Target
Steroid 17-alpha-hydroxylase/17,20 lyase
Ligand
BDBM50128548
Substrate
n/a
Meas. Tech.
ChEMBL_50523 (CHEMBL661140)
Ki
56.50±n/a nM
Citation
 Clement, OOFreeman, CMHartmann, RWHandratta, VDVasaitis, TSBrodie, AMNjar, VC Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. J Med Chem 46:2345-51 (2003) [PubMed]  Article 
Target
Name:
Steroid 17-alpha-hydroxylase/17,20 lyase
Synonyms:
CP17A_HUMAN | CYP17 | CYP17A1 | CYPXVII | Cytochrome P450 17A1 | Cytochrome P450 C17 (CYP17 ) | Cytochrome P450 C17 (CYP17) | Cytochrome P450 CYP17 | Cytochrome P450-C17 | Cytochrome P450-C17 (CYP17) | P450-C17 | S17AH | Steroid 17-alpha-Monooxygenase (CYP17) | Steroid 17-alpha-hydroxylase/17,20 lyase | Steroid 17-alpha-monooxygenase | cytochrome P450 monooxygenase 17 alpha hydroxylase/17,20-lyase (CYP17)
Type:
Enzyme
Mol. Mass.:
57382.42
Organism:
Homo sapiens (Human)
Description:
E.coli expressing human CYP17
Residue:
508
Sequence:
MWELVALLLLTLAYLFWPKRRCPGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKYGPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAHWQLHRRLAMATFALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVISLICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRNDLLNKILENYKEKFRSDSITNMLDTLMQAKMNSDNGNAGPDQDSELLSDNHILTTIGDIFGAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREVLRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNEKEWHQPDQFMPERFLNPAGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIPKVVFLIDSFKVKIKVRQAWREAQAEGST
  
Inhibitor
Name:
BDBM50128548
Synonyms:
1-(1-Biphenyl-4-yl-2-phenyl-methyl)-1H-imidazole | 1-(Biphenyl-4-yl-phenyl-methyl)-1H-imidazole (bifonazole) | 1-(Biphenyl-4-yl-phenyl-methyl)-1H-imidazole( Bifanozole) | 1-(Biphenyl-4-yl-phenyl-methyl)-1H-imidazole(Bifonazole) | 1-(biphenyl-4-yl-phenyl-methyl)-1H-imidazole | BIFONAZOLE | CHEMBL277535 | US9144538, Bifonazole | cid_2378
Type:
Small organic molecule
Emp. Form.:
C22H18N2
Mol. Mass.:
310.3917
SMILES:
c1cn(cn1)C(c1ccccc1)c1ccc(cc1)-c1ccccc1
Structure:
Search PDB for entries with ligand similarity: